Anthem · Semaglutide · US health-plan appeal rights

Semaglutide denied for missing prior authorization by Anthem?

Q: How long do I have to appeal a Anthem Semaglutide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem semaglutide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Semaglutide

## Anthem Prior Authorization for Semaglutide (Ozempic/Wegovy): The Mechanic Behind the Denial

When Anthem returns a prior-auth-required denial for semaglutide, the rejection is not a coverage decision on the merits — it is a procedural gate. Anthem BCBS plans route GLP-1 PA requests through IngenioRx/CarelonRx (Anthem's in-house PBM since the 2020 transition from Express Scripts), and the determination is governed by Clinical UM Guideline CG-DRUG-86 (Glucagon-Like Peptide-1 Receptor Agonists) for the T2DM indication and CG-DRUG-119 (Anti-Obesity Agents) for Wegovy. Until a complete PA packet lands in the CarelonRx queue with the right clinical hooks, the claim sits in administrative denial — no MHPAEA, no medical-necessity argument changes that.

### What CG-DRUG-86 Actually Requires

For Ozempic (semaglutide for T2DM), Anthem's published criteria require: (1) confirmed T2DM diagnosis (ICD-10 E11.x), (2) HbA1c ≥6.5% documented within the prior 12 months OR a pre-existing T2DM diagnosis with documented metformin trial/contraindication, and (3) prescriber attestation that the patient is not using semaglutide for weight loss alone. The HbA1c lab value is the single most-cited missing element — submissions that paste a problem-list entry without the numeric A1c and collection date get auto-denied at the CarelonRx adjudication layer before a pharmacist ever sees the file.

### Procedural Levers

File the PA through CoverMyMeds or CarelonRx provider portal (fax 1-844-490-4882 is the fallback). For fully-insured Anthem plans, the federal step-therapy override pathway under 29 USC §1185d applies if Anthem is requiring a metformin/SGLT2 step first and the patient has documented intolerance — invoke it explicitly in the PA narrative. For ERISA self-funded plans, 29 CFR §2560.503-1(g) requires Anthem to disclose the specific clinical rule it relied on; if the denial letter just says "PA required" without citing CG-DRUG-86, that is itself a disclosure violation and grounds for a 503-1(h) full and fair review request.

If the patient is on Anthem Medicare Advantage, semaglutide for weight loss is statutorily excluded under 42 USC §1395w-102(e)(2)(A) — only the T2DM indication is reimbursable, and the PA must be framed accordingly. For Anthem MA expedited PA, 42 CFR §422.568 mandates a 72-hour turnaround when delay would jeopardize health.

### Tactical Tip

Before appealing, pull the CG-DRUG-86 version dated within the last 6 months from anthem.com/provider/policies and quote the exact criterion number you meet. Attach the HbA1c lab report (not the chart note), the E11.9 ICD code, and a one-line metformin history. PA approvals on resubmission with this packet routinely clear within 48 hours — far faster than a Level 1 appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Semaglutide

Other denial reasons for Anthem Semaglutide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.